It’s full-on conference season; so, naturally I find myself thinking about the Disruptive Innovations to Advance Clinical Trials (DPharm) conference I attended last week, and looking forward to attending Medicine X in Palo Alto this week.
DPharm is largely an industry-focused event, attended by those who share an interest in bringing radical change to the ways that clinical trials are conducted. It is co-chaired by a set of pharma executives that includes Craig Lipset of Pfizer; Andreas Koester of Jannsen; John Orloff, MD of Novartis; and Jeff Kasher of Eli Lilly. Jeff is the sponsor of our clinical open innovation work as well as other Lilly clinical trial transformation efforts, and leads the charge for us in bringing patient centricity to clinical development. In his conference kick-off, Jeff shared perspective on how to progress innovation by saying “A brilliant idea with no uptake has no value.”
I felt privileged to participate alongside established industry leaders both this year and last.
Here are a few key takeaways from this year’s conference:
1. Pharma’s commitment to collaboration is real. As evidence, look to TransCelerate BioPharma, Inc., a non-profit consortium of 17 pharmaceutical companies who are working together to solve common problems in drug research and development. After only one year of operation, the consortium has set a number of actionable deliverables, and is poised to make a real difference in clinical trial efficiency. The intent of the consortium is to allow the industry to collaborate in common areas like site qualification and training, risk-based monitoring, coordination with regulators and leveraging data standards. TransCelerate is all about making clinical research more efficient, and improved efficiency means valuable treatments can be delivered to patients more quickly and at a lower cost.
Similarly, the Investigator Databank, sponsored by Jannsen, Merck and Lilly, has also progressed in its objective to share investigator site data. By pooling important data from investigator sites like training records and site qualification data into a single source, it’s easier to identify the appropriate sites to conduct clinical trials. I was impressed to hear that more than 80 percent of study sites who have been approached have been willing to opt-in to sharing their information in the data bank.
2. Steps are being taken to provide patients access to their clinical trial data. Pfizer‘s announcement of its upcoming launch of their Blue Button pilot caused quite a bit of excitement among the conference attendees. The first-of-its-kind initiative will enable patients who have participated in clinical trials to download their individual clinical trial data using the Blue Button standard. Clinical trial participants will be able to download and use their data as they wish – with caregivers and providers, to add to their personal health records, or in any way of their choosing. Craig Lipset, Pfizer’s Head of Clinical Innovation explained the company’s reason for launching this project by saying, “Sometimes, it’s just the right thing to do.”
3. Clinical trials are being integrated into day-to-day living. Walgreens and Novartis have continued with the pilot program they announced last year in which they integrate certain aspects of clinical research into patients’ regular pharmacy visits. Also, Medidata and Spaulding Clinical have partnered for their first clinical trial, which will use mhealth devices to “evaluate the impact of mobile and cloud-based technology on patient engagement for improved health outcomes in the diabetes community.” The trial will serve to demonstrate how tracking devices like Fitbit can be combined with Withings health-tracking scale to collect data in any clinical trial setting.
4. eConsent is happening. Joe Kim of Shire has shared how the patient experience can be better, audit-ability can be improved and overall efficiency can be gained by capturing clinical trial eConsent on an iPad. It became evident during the conference that most pharma companies are either piloting an eConsent program or are planning to pilot one.
One Thing I Wish There Was More of…
I am struck by the potential value of these efforts and inspired by the industry’s alignment on them. However, if there’s one thing I would like to see more of at DPharm, it would be a bit more spirited discussion on how the implementation of these efforts lands on stakeholders. I would have liked to have heard more direct engagement with those who will be most affected by the changes, like site investigators and, most importantly, patients.
We did hear a bit of that kind of feedback during the “The Investigator POV: What Disruption is Needed to Achieve Better Relationships” panel discussion. When the panel of site investigators was asked about what they wish sponsors would change in clinical trials they mentioned streamlined payment, more input into trial design, a better compensation model for screening failures and, overall, a bit of a behavior change between trial sponsor and site investigator. It was great to hear a number of diverse perspectives and see opportunities there for alignment. I just wish there was a few more opportunities to hear those perspectives in other sessions.
There is no doubt that the industry is aware of the need for change. It’s extremely encouraging to see year-to-year progress being made in driving efficiency and improving the patient experience in clinical trials. DPharm is THE place for the pharma industry to come together to share ideas in clinical trial innovation and forge collaborations. It’s an unmatched opportunity to build individual relationships and to network. It’s also a place to catch a glimpse of the future of clinical trials, and a place where you can see the hope for better treatments turned into actionable ideas to disrupt and innovate in clinical trials.
This week, I’m at Medicine X, which is an entirely different beast. Here’s the description from their website:
Medicine X is an academic conference designed for everyone. As part of that inclusive mission, we’ve created special programs designed to encourage ePatients, academic scholars and students to participate in the conference. We are proud to announce our Global Access Program, which will allow anyone who can’t join us at Stanford to attend virtually through a high-quality streaming webcast. And the price to view the webcast is one that anyone can afford: it’s free.
It will be interesting to see how the themes from DPharm crossover into MedicineX, and to gain some additional insights from patients and clinicians on how innovation can progress in clinical research. I’ll provide a recap of the conference soon after I return.
In the meantime, we’d love to hear what you think about the things we’ve shared from DPharm. Let us know in the comments below.